Evidence map›Paper›PMID 35558606›Full record

ArticleRSC advances2018

Retracted Article: Long noncoding RNA PCA3 regulates glycolysis, viability and apoptosis by mediating the miR-1/CDK4 axis in prostate cancer.

Shuo Gu, Xiaobing Niu, Fei Mao, Zongyuan Xu

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shuo GuDepartment of Urology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University No. 1, West Huanghe Road, Huaiyin District Huaian City Jiangsu Province 223300 P. R. China ldyyzhao@126.com +86-139-5234-6996.
Xiaobing NiuDepartment of Urology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University No. 1, West Huanghe Road, Huaiyin District Huaian City Jiangsu Province 223300 P. R. China ldyyzhao@126.com +86-139-5234-6996.
Fei MaoDepartment of Urology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University No. 1, West Huanghe Road, Huaiyin District Huaian City Jiangsu Province 223300 P. R. China ldyyzhao@126.com +86-139-5234-6996.
Zongyuan XuDepartment of Urology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University No. 1, West Huanghe Road, Huaiyin District Huaian City Jiangsu Province 223300 P. R. China ldyyzhao@126.com +86-139-5234-6996.ORCID 0000-0002-4169-1421
Huaian First People’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is one of the common tumor malignancies in men worldwide. Although long noncoding RNAs (lncRNAs) have been demonstrated to play essential roles in the progression of prostate cancer, the roles and potential mechanism of lncRNA prostate cancer antigen 3 (PCA3) remain poorly understood. In the present study, we investigated the role of PCA3 in aerobic glycolysis, viability and apoptosis in prostate cancer cells and probed the interaction between PCA3 and microRNA-1 (miR-1)/cyclin-dependent kinase 4 (CDK4). Here we found that PCA3 and CDK4 were up-regulated while miR-1 was down-regulated in prostate cancer tissues and cells. Moreover, knockdown of PCA3 inhibited aerobic glycolysis and viability and induced apoptosis in prostate cancer cells. Intriguingly, PCA3 was bound to miR-1 and inhibition of miR-1 reversed the regulatory effect of PCA3 knockdown on aerobic glycolysis, viability and apoptosis in prostate cancer cells. Besides, CDK4 was indicated as a target of miR-1 and it was regulated by PCA3 through functioning as a competing endogenous RNA (ceRNA) of miR-1 in prostate cancer cells. The results indicated that PCA3 might drive aerobic glycolysis, viability and apoptosis by regulating the miR-1/CDK4 axis in prostate cancer cells, providing a promising avenue for treatment of prostate cancer.

Identifiers

PMID35558606
PMCPMC9089421
OpenAlexW2899760643

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.